Search Results
Mar 10, 2026, 07:00 ET Kingsoft Cloud to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 25, 2025
https://register-conf.media-server.com/register/BI62cd2e3d362448ba8a49e0d8c7304f2c. Once preregistration has been completed, participants will receive dial-in numbers, direct event passcode,
More news about: Kingsoft Cloud Holdings Limited
Mar 09, 2026, 17:31 ET Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
IMDELLTRA (tarlatamab) (Amgen), and others.Boehringer Ingelheim and Oxford BioTherapeutics' BI 764532 is an investigational IgG-like DLL3/CD3 T-cell engager under development by Boehringer Ingelheim for the potential treatment of patients with LCNEC. The molecule (also known as OBT620) originated
More news about: DelveInsight Business Research, LLP
Mar 09, 2026, 07:30 ET ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA® mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering
More news about: ImmunityBio
Mar 09, 2026, 07:00 ET NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart (AT-1501), with the goal of supporting durable, immune-protected islet replacement and advancing a potential functional cure for Type 1 Diabetes.Eledon's tegoprubart is a next-generation anti-CD40L monoclonal antibody designed
More news about: NewcelX Ltd.
Mar 09, 2026, 02:28 ET Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
efficacy evaluation, as well as druggability assessment. We have also developed multiple proprietary technology platforms, including LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), TOPiKinectics (ADC platform), which serve as the cornerstone for our continued
More news about: Leads Biolabs
Mar 07, 2026, 21:17 ET Superteam Wheels stringe una partnership strategica triennale con GCN Italia, espandendo ulteriormente la presenza sul mercato europeo
https://mma.prnewswire.com/media/2927816/406e2629a2240e552cd8af7ed376b3ce.jpgFoto -
More news about: Superteam
Mar 07, 2026, 03:30 ET Superteam Wheels Enters Three-Year Strategic Partnership with GCN Italia, Further Expanding European Market Presence
https://mma.prnewswire.com/media/2927816/406e2629a2240e552cd8af7ed376b3ce.jpgPhoto -
More news about: Superteam
Mar 07, 2026, 03:30 ET Superteam Wheels geht eine dreijährige strategische Partnerschaft mit GCN Italia ein und baut damit seine europäische Marktpräsenz weiter aus
https://mma.prnewswire.com/media/2927816/406e2629a2240e552cd8af7ed376b3ce.jpgFoto -
More news about: Superteam
Mar 07, 2026, 03:30 ET Superteam Wheels firma una alianza estratégica de tres años con GCN Italia
https://mma.prnewswire.com/media/2927816/406e2629a2240e552cd8af7ed376b3ce.jpgFoto -
More news about: Superteam
Mar 07, 2026, 03:30 ET Superteam Wheels conclut un partenariat stratégique de trois ans avec GCN Italia, renforçant ainsi sa présence sur le marché européen.
https://mma.prnewswire.com/media/2927816/406e2629a2240e552cd8af7ed376b3ce.jpgPhoto -
More news about: Superteam
Mar 06, 2026, 07:03 ET CARsgen Therapeutics Announces 2025 Annual Results
results of an IIT have been presented at the 67th ASH in December 2025.CT1190B (KJ-C2219) is an allogeneic CAR T-cell product candidate targeting CD19/CD20 deploying our THANK-u Plus™ technology, for hematologic malignancies and autoimmune diseases. The IITs have been initiated for R/R B-NHL, and for
More news about: CARsgen Therapeutics
Mar 05, 2026, 17:31 ET Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight
signaling. In preclinical testing, it showed strong receptor occupancy and robust inhibition of TSLP pathways. Verekitug also reduced cytokine release from CD4+ T cells and ILC2s and completely prevented allergic skin responses in a non-human primate model, indicating potential effectiveness across multiple
More news about: DelveInsight Business Research, LLP
Mar 05, 2026, 15:55 ET Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
TECVAYLI®TECVAYLI® (teclistamab-cqyv) is a first-in-class, bispecific T-cell engager antibody therapy that uses innovative science to activate the immune system by binding to the CD3 receptor expressed on the surface of T-cells and to the B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some
More news about: Johnson & Johnson
Mar 05, 2026, 13:31 ET Fapon Biopharma présente la plateforme CD3/TCR VHH TCE de nouvelle génération au cours du 19e Forum européen annuel des PDG des sciences de la vie
Fapon's Human/Cyno Cross-Reactive CD3/TCR VHH Platform » (Lancement de la prochaine génération de TCE : la plateforme VHH CD3/TCR humaine/cyno à réactivité croisée de Fapon ), Fapon Biopharma présentera sa plateforme d'engagement des cellules T (TCE) basée sur le CD3/TCR VHH, une approche innovante conçue
More news about: Fapon Biopharma
Mar 05, 2026, 10:16 ET Lipid Nanoparticles Market to Reach $3.1 Billion, Globally, by 2033 at 13.1% CAGR: Allied Market Research
https://www.alliedmarketresearch.com/purchase-enquiry/A323703 Key Players ABP Biosciences, LLC. Merck KGaA Cytiva CD Bioparticles CordenPharma Precigenome LLC. Beam Therapeutics Acuitas Therapeutics GENEVANT SCIENCES CORPORATION Helix
More news about: Allied Market Research
Mar 05, 2026, 07:38 ET Antlara Dental, a Turkish dental practice, is standardising clinical practices based on GDC principles
Info:Address: Hanover Square, London W1S Telephone: +44 7770 537 469Antalya Clinic: Zümrütova, Sinanoğlu Cd. No:53A, Muratpasa/Antalya, TürkiyeTelephone: +90 (541) 120 42 08 Email: [email protected]
More news about: Antlara Dental
Mar 05, 2026, 01:24 ET Fapon Biopharma presentará la plataforma CD3/TCR VHH TCE de próxima generación
presentación titulada "Desbloqueando la Próxima Generación de TCE: Plataforma CD3/TCR VHH con Reactividad Cruzada Humana/Cyno de Fapon", Fapon Biopharma presentará su plataforma patentada de captadores de células T (TCE) basada en CD3/TCR VHH, un enfoque innovador diseñado para superar los desafíos de desarrollo
More news about: Fapon Biopharma
Mar 05, 2026, 01:24 ET Fapon Biopharma präsentiert CD3/TCR VHH TCE-Plattform der nächsten Generation auf dem 19. Annual European Life Sciences CEO Forum
In einem Vortrag mit dem Titel „Unlocking the Next Generation of TCEs: Fapon's Human/Cyno Cross-Reactive CD3/TCR VHH Platform" wird Fapon Biopharma seine proprietäre CD3/TCR VHH-basierte T-Cell Engager (TCE)-Plattform vorstellen, einen innovativen Ansatz, der entwickelt wurde, um die mit
More news about: Fapon Biopharma
Mar 04, 2026, 23:58 ET iFLYTEK Launches AI Translation Earbuds in the U.S.
for long meetings.Hi-Res Audio: Hi-Res certified with dynamic bass compensation and adaptive EQ, delivering high-fidelity sound beyond CD quality for translation, calls, and music.Introductory Sales DetailsiFLYTEK's AI Translation Earbuds will be available starting
More news about: iFLYTEK Co., Ltd.
Mar 04, 2026, 20:40 ET 以千分之一劑量 CAR-T 實現血液瘤與紅斑狼瘡100%完全緩解，晶泰孵化企業萊芒生物完成近2億元融資，「平價」新型高效細胞療法開啟臨床轉化
I期臨床研究，加速推進其自動化生產工藝研發與驗證，以及啟動代謝增強型實體瘤細胞治療藥物的臨床轉化。在晶泰科技的投資孵化與研發賦能下，萊芒生物聚焦創新腫瘤免疫治療藥物管線的研發，開發並持續升級了其獨有的 META 10 與 META 10-AI 兩大 AI+代謝重編程技術平台，實現對耗竭 T 細胞代謝的精準調控，從而顯著增強其增殖能力、細胞殺傷活性及免疫記憶功能。相比傳統 CAR-T 療法成本高昂、響應率低、毒副作用顯著等臨床難題，萊芒生物開發的代謝增強型 CD19 CAR-T 療法，以更低劑量、更低價快速的制備過程，實現更高的臨床響應率和更優的安全性，推動患者達到完全緩解，為安全高效的新一代 「平價」 CAR-T 療法上市乃至進入醫保奠定基礎。目前，萊芒生物多條管線進入 IIT（研究者發起臨床）階段，適應症涵蓋惡性血液瘤、實體瘤以及自身免疫性疾病等多個具備廣闊治療前景的重大疾病領域，並展現出極強的治療潛力。
More news about: 晶泰科技
Mar 04, 2026, 09:15 ET Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
efficacy results from an investigator‑initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox‑cxdl) administered prior to commercial CD19‑directed CAR‑T therapy in patients with high‑risk relapsed or refractory diffuse large B‑cell lymphoma (DLBCL). The trial was conducted by lead investigator,
More news about: Citius Oncology, Inc.
Mar 04, 2026, 07:07 ET OpsGuru Achieves Designation in the AWS Managed Services Provider Program, Driving Continuous Cloud Operations and AI-Driven Innovation
cloud-native development expertise directly into the software development lifecycle. OpsGuru provides the specialized coding, automated testing, and CI/CD skills required to build and deploy modern, microservices-based applications at enterprise scale.To learn more about how OpsGuru leverages
More news about: OpsGuru Canada Inc.
Mar 04, 2026, 07:07 ET OpsGuru Achieves Designation in the AWS Managed Services Provider Program, Driving Continuous Cloud Operations and AI-Driven Innovation
cloud-native development expertise directly into the software development lifecycle. OpsGuru provides the specialized coding, automated testing, and CI/CD skills required to build and deploy modern, microservices-based applications at enterprise scale.To learn more about how OpsGuru leverages
More news about: OpsGuru Canada Inc.
Mar 04, 2026, 02:00 ET Fapon Biopharma to Present Next-Generation CD3/TCR VHH TCE Platform at 19th Annual European Life Sciences CEO Forum
In a presentation titled "Unlocking the Next Generation of TCEs: Fapon's Human/Cyno Cross-Reactive CD3/TCR VHH Platform", Fapon Biopharma will showcase its proprietary CD3/TCR VHH-based T-cell engager (TCE) platform, an innovative approach designed to overcome developability and flexibility
More news about: Fapon Biopharma
Mar 03, 2026, 17:00 ET Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
certain haematological cancers. Specifically, ATG-201 is a CD19 targeting bispecific TCE incorporating steric hindrance masking technology, designed to eliminate CD19-expressing B cells. This bispecific interaction with T and B cells through CD3 and CD19 has demonstrated potential in treating B cell-driven
More news about: Antengene Corporation Limited